Latest news
The ASCO Drug Race Still Runs Through Genomic Testing
Foundation Medicine’s ASCO research package shows that comprehensive profiling, ctDNA and HRD signatures are becoming the access infrastructure behind modern precision oncology.
Cancer Pharmacogenomics Exposes an Ancestry Gap in Routine Testing
Biomarker Testing Is Rising, But Eligibility Still Gets Lost
Colon Cancer MRD Testing Is Nearing the Access Threshold
Breast Cancer Blood Tests Could Bring Treatment Decisions Earlier
Lung Cancer Screening Now Has a Diagnostic Bottleneck
Liquid Biopsy Turns Precision Oncology Into an NHS Delivery Test
Molecular Testing Is Europe’s Real Precision Oncology Infrastructure
Cancer Approval Is No Longer Enough
Europe’s Cancer Inequality Map Becomes a Performance Test
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.